Subscribe
Sign in
Home
Podcast
The Book
FemmeHealth Alliance
Signal Not Noise
About
Latest
Top
Discussions
The Billion Dollar Blind Spot Began in a Doctor’s Office
The story behind The Billion Dollar Blind Spot and the structural forces reshaping healthcare innovation and capital allocation.
May 17
•
Maryann
11
2
3
The Wealth-Health Convergence
Why the largest intergenerational wealth transfer in history may become the catalyst for a structural repricing in women’s health investing.
May 16
•
Maryann
10
1
3
UCB Just Paid $2.2 Billion for an Autoimmune Platform. The Indication List Tells You More Than the Deal Price.
UCB’s acquisition of Candid Therapeutics is being framed as a next-generation immunology platform deal. But beneath the immune-reset narrative lies a…
May 12
•
Maryann
16
4
4
The Future of Medicine Is Being Built on Incomplete Biology
A new Nature Neuroscience commentary warns that phasing out animal research before female biology is well understood could lock historical male bias…
May 9
•
Maryann
28
4
8
Two Approved Drugs. The Same Structural Problem. What the Menopause Market Is Actually Telling Investors.
The first non-hormonal menopause drug launched in 2023. Two and a half years later, the commercial case has not arrived. Bayer launched its competitor…
May 5
•
Maryann
9
1
3
What Menopause Is Actually Doing to the Heart
The estrogen model gave medicine a framework. New research suggests it was never the complete picture and the capital implications haven't caught up.
May 3
•
Maryann
33
8
8
April 2026
Sun Pharma Agreed to Pay $11.75 Billion for Organon. The Portfolio Is Women's Health. The Thesis Is Not.
The largest overseas acquisition in Indian pharmaceutical history transferred the world's biggest dedicated women's health portfolio to a biosimilar…
Apr 30
•
Maryann
3
4
2
The Menopause Information Crisis
Some markets follow a familiar script: a need emerges, founders respond, capital flows, and eventually, the sector matures.
Apr 16
•
Maryann
and
Hotflash Inc
15
2
9
31:15
The Operation That Shouldn't Still Be Happening
What a seven-minute procedure reveals about the real opportunity in women's health investing
Apr 12
•
Maryann
17
5
Gilead Just Paid $5 Billion for a European Biotech. The Indication Was Ovarian Cancer. That's Not a Coincidence.
The largest private European biotech exit in history followed a pattern that was visible before the announcement. Here's how to read it and what it…
Apr 8
•
Maryann
3
1
The Great Wealth Transfer and Women's Health: Why These Are the Same Story
For the first time in history, the people with the capital, the lived experience, and the investment sophistication are the same people. Here is what…
Apr 4
•
Maryann
21
6
11
Organon Is Telling You Exactly What It Is and the Exit Math for Women's Health Has Changed
The sequence of decisions Organon made between October 2025 and March 2026 changes the exit landscape for every early-stage company building in…
Apr 4
•
Maryann
3
1
This site requires JavaScript to run correctly. Please
turn on JavaScript
or unblock scripts
